MAC-321

Wyeth is now a wholly owned subsidiary of Pfizer · Phase 2 active Small molecule

At a glance

Generic name	MAC-321
Sponsor	Wyeth is now a wholly owned subsidiary of Pfizer
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study Evaluating MAC-321 in Colorectal Cancer (PHASE2)
Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy (PHASE2)
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MAC-321 CI brief — competitive landscape report
MAC-321 updates RSS · CI watch RSS
Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI